Chiquita Brooks-LaSure (Photo by Caroline Brehman/CQ Roll Call via AP Images)

Just the idea of Aduhelm's long-term fi­nan­cial risks has CMS jack­ing up pre­mi­ums, de­ductibles for 2022

Al­though sales of Bio­gen’s ex­pen­sive new Alzheimer’s drug have been ane­mic since the ap­proval in June, the prospect of CMS even­tu­al­ly pay­ing for it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA